Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603926 · ClinicalTrials.gov registry record · Phase 2
Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
A Phase 2 study, sponsored by Randi J. Hagerman, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02603926: Completed Phase 2 study, sponsored by Randi J. Hagerman, MD.
NCT02603926 is a Phase 2 study that has completed, run by Randi J. Hagerman, MD. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02603926, a Phase 2 study, has completed, sponsored by Randi J. Hagerman, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
Primary Outcome
California Verbal Learning Test II (CVLT2) is an assessment measuring working memory. Trials 1-5 measure the total number of words remembered after 5 repeated trials and are summed to generate a raw score (called Trial 1-5 Free Recall Total Raw Score) ranging from 0 to 80, with higher scores reflecting better working memory. Mean and standard deviation for raw score at baseline/pre-treatment and at 14 weeks/post-treatment are presented here.
Interventions
- DRUG Allopregnanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
What the finished NCT02603926 record still lists
NCT02603926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Allopregnanolone is the first listed.
NCT02603926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02603926 about?
NCT02603926 is a clinical study titled "Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone". The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
What is the current status of trial NCT02603926?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-10. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02603926?
The interventions under investigation include: Allopregnanolone (DRUG).
Who is sponsoring clinical trial NCT02603926?
This trial is sponsored by Randi J. Hagerman, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02603926's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia